103 related articles for article (PubMed ID: 27490860)
1. 3-Chlorotyramine Acting as Ligand of the D2 Dopamine Receptor. Molecular Modeling, Synthesis and D2 Receptor Affinity.
Angelina E; Andujar S; Moreno L; Garibotto F; Párraga J; Peruchena N; Cabedo N; Villecco M; Cortes D; Enriz RD
Mol Inform; 2015 Jan; 34(1):28-43. PubMed ID: 27490860
[TBL] [Abstract][Full Text] [Related]
2. Tetrahydroisoquinolines acting as dopaminergic ligands. A molecular modeling study using MD simulations and QM calculations.
Andujar S; Suvire F; Berenguer I; Cabedo N; Marín P; Moreno L; Dolores Ivorra M; Cortes D; Enriz RD
J Mol Model; 2012 Feb; 18(2):419-31. PubMed ID: 21523539
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling study of dihydrofolate reductase inhibitors. Molecular dynamics simulations, quantum mechanical calculations, and experimental corroboration.
Tosso RD; Andujar SA; Gutierrez L; Angelina E; Rodríguez R; Nogueras M; Baldoni H; Suvire FD; Cobo J; Enriz RD
J Chem Inf Model; 2013 Aug; 53(8):2018-32. PubMed ID: 23834278
[TBL] [Abstract][Full Text] [Related]
4. Searching the "biologically relevant"conformation of dopamine: a computational approach.
Andujar SA; Tosso RD; Suvire FD; Angelina E; Peruchena N; Cabedo N; Cortes D; Enriz RD
J Chem Inf Model; 2012 Jan; 52(1):99-112. PubMed ID: 22146008
[TBL] [Abstract][Full Text] [Related]
5. 2,3,9- and 2,3,11-trisubstituted tetrahydroprotoberberines as D2 dopaminergic ligands.
Párraga J; Cabedo N; Andujar S; Piqueras L; Moreno L; Galán A; Angelina E; Enriz RD; Ivorra MD; Sanz MJ; Cortes D
Eur J Med Chem; 2013 Oct; 68():150-66. PubMed ID: 23974015
[TBL] [Abstract][Full Text] [Related]
6. Combined MD/QTAIM techniques to evaluate ligand-receptor interactions. Scope and limitations.
Rojas S; Parravicini O; Vettorazzi M; Tosso R; Garro A; Gutiérrez L; Andújar S; Enriz R
Eur J Med Chem; 2020 Dec; 208():112792. PubMed ID: 32949964
[TBL] [Abstract][Full Text] [Related]
7. Conformational and electronic study of dopamine interacting with the D
Tosso RD; Parravicini O; Zarycz MNC; Angelina E; Vettorazzi M; Peruchena N; Andujar S; Enriz RD
J Comput Chem; 2020 Aug; 41(21):1898-1911. PubMed ID: 32511790
[TBL] [Abstract][Full Text] [Related]
8. The Universal 3D QSAR Model for Dopamine D
Zięba A; Żuk J; Bartuzi D; Matosiuk D; Poso A; Kaczor AA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540025
[TBL] [Abstract][Full Text] [Related]
9. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
10. Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.
Schwalbe T; Kaindl J; Hübner H; Gmeiner P
Bioorg Med Chem; 2017 Oct; 25(19):5084-5094. PubMed ID: 28666858
[TBL] [Abstract][Full Text] [Related]
11. The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics.
Kaczor AA; Jörg M; Capuano B
J Mol Model; 2016 Sep; 22(9):203. PubMed ID: 27491852
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
[TBL] [Abstract][Full Text] [Related]
13. A QM protein-ligand investigation of antipsychotic drugs with the dopamine D2 Receptor (D2R).
Ekhteiari Salmas R; Serhat Is Y; Durdagi S; Stein M; Yurtsever M
J Biomol Struct Dyn; 2018 Aug; 36(10):2668-2677. PubMed ID: 28805144
[TBL] [Abstract][Full Text] [Related]
14. Biotinylated-spiperone ligands for quantum dot labeling of the dopamine D2 receptor in live cell cultures.
Tomlinson ID; Kovtun O; Crescentini TM; Rosenthal SJ
Bioorg Med Chem Lett; 2019 Apr; 29(8):959-964. PubMed ID: 30808590
[TBL] [Abstract][Full Text] [Related]
15. Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.
Li W; Zhang L; Xu L; Yuan C; Du P; Chen J; Zhen X; Fu W
Chem Biol Drug Des; 2016 Oct; 88(4):599-607. PubMed ID: 27232055
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
Fu W; Shen J; Luo X; Zhu W; Cheng J; Yu K; Briggs JM; Jin G; Chen K; Jiang H
Biophys J; 2007 Sep; 93(5):1431-41. PubMed ID: 17468175
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydroisoquinolines functionalized with carbamates as selective ligands of D2 dopamine receptor.
Parravicini O; Bogado ML; Rojas S; Angelina EL; Andujar SA; Gutierrez LJ; Cabedo N; Sanz MJ; López-Gresa MP; Cortes D; Enriz RD
J Mol Model; 2017 Sep; 23(9):273. PubMed ID: 28866777
[TBL] [Abstract][Full Text] [Related]
18. Structure-5-HT/D
Żmudzki P; Satała G; Chłoń-Rzepa G; Bojarski AJ; Kazek G; Siwek A; Gryboś A; Głuch-Lutwin M; Wesołowska A; Pawłowski M
Arch Pharm (Weinheim); 2016 Oct; 349(10):774-784. PubMed ID: 27510801
[TBL] [Abstract][Full Text] [Related]
19. The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D
Draper-Joyce CJ; Michino M; Verma RK; Klein Herenbrink C; Shonberg J; Kopinathan A; Scammells PJ; Capuano B; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
Biochem Pharmacol; 2018 Feb; 148():315-328. PubMed ID: 29325769
[TBL] [Abstract][Full Text] [Related]
20. Modeling of Dopamine D2 Receptor - Overview of 35-Year Evolution.
Sukalovic V; Soskic V; Kostic-Rajacic S
Curr Med Chem; 2015; 22(25):2972-90. PubMed ID: 26180002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
